CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled
Drug / intervention
ixabepilone +2 moredrug
Likely dose
Ixabepilone IV (specific dose not stated in provided text)AI-extracted
Key inclusion· 7
  • ✓Histologically proven malignant glioma (anaplastic astrocytoma or glioblastoma multiforme) that is progressive or recurrent after radiation therapy +/- chemotherapy
  • ✓Measurable progressive or recurrent disease by MRI or CT imaging
  • ✓Maximum 2 prior chemotherapy regimens
  • ✓Karnofsky performance status ≥60%
Key exclusion· 6
  • ✕Serious concurrent infection or medical illness jeopardizing safe treatment
  • ✕Pregnant or breast-feeding
  • ✕More than 2 prior chemotherapy regimens
  • ✕Receiving concurrent investigational agents

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00045708
NCT00045708Phase 2Completed
CompareCT.gov

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas

National Cancer Institute (NCI)·interventional·Posted Jan 27, 2003·Updated Oct 18, 2017

In Brief

A Phase 2 clinical trial evaluating ixabepilone, pharmacological study, and 1 other intervention for Adult Anaplastic Astrocytoma and 3 related conditions. Completed, enrolled 57 participants across 5 sites.

Detailed Summary

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase I/II trial is studying the side effects and best dose of ixabepilone and how well it works in treating patients with recurrent glioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartOct 1, 2002
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 23.4 years ago

Interventions

ixabepilonedrug

Given IV

pharmacological studyother

Correlative studies

Anticonvulsantdrug

Drugs that induce hepatic Metabolic enzymes